468 related articles for article (PubMed ID: 21326118)
21. Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors.
Lunsford AJ; Whelan K; McCormick K; McLaren JF
Fertil Steril; 2014 Jan; 101(1):227-31. PubMed ID: 24083876
[TBL] [Abstract][Full Text] [Related]
22. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T; Barrière P; Masson D
Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
[TBL] [Abstract][Full Text] [Related]
23. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies.
Lie Fong S; Lugtenburg PJ; Schipper I; Themmen AP; de Jong FH; Sonneveld P; Laven JS
Hum Reprod; 2008 Mar; 23(3):674-8. PubMed ID: 18216040
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant hormonal therapy in perimenopausal patients.
Pinto Marín A; Ballesteros García AI; Izarzugaza Perón Y; Mansó Sánchez L; López-Tarruella Cobo S; Zamora Auñón P
Adv Ther; 2011 Sep; 28 Suppl 6():39-49. PubMed ID: 21922394
[TBL] [Abstract][Full Text] [Related]
25. Controversies in preservation of ovary function and fertility in patients with breast cancer.
Gerber B; Dieterich M; Müller H; Reimer T
Breast Cancer Res Treat; 2008 Mar; 108(1):1-7. PubMed ID: 17457668
[TBL] [Abstract][Full Text] [Related]
26. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
Ravdin PM; Fritz NF; Tormey DC; Jordan VC
Cancer Res; 1988 Feb; 48(4):1026-9. PubMed ID: 3123050
[TBL] [Abstract][Full Text] [Related]
27. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
Ryan PD; Goss PE
Oncologist; 2006; 11(7):718-31. PubMed ID: 16880231
[TBL] [Abstract][Full Text] [Related]
29. Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels.
Meng K; Tian W; Zhou M; Chen H; Deng Y
World J Surg Oncol; 2013 May; 11():101. PubMed ID: 23688389
[TBL] [Abstract][Full Text] [Related]
30. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
31. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
32. Measuring ovarian function in young cancer survivors.
Su HI
Minerva Endocrinol; 2010 Dec; 35(4):259-70. PubMed ID: 21178920
[TBL] [Abstract][Full Text] [Related]
33. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S;
J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042
[TBL] [Abstract][Full Text] [Related]
34. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.
Reh A; Oktem O; Oktay K
Fertil Steril; 2008 Nov; 90(5):1635-9. PubMed ID: 18166178
[TBL] [Abstract][Full Text] [Related]
35. [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy].
Yasumura T; Oka T; Honjo H; Okada H
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2947-52. PubMed ID: 3140733
[TBL] [Abstract][Full Text] [Related]
36. Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
van Hellemond IEG; Vriens IJH; Peer PGM; Swinkels ACP; Smorenburg CH; Seynaeve CM; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; Kitzen JJEM; de Boer M; de Roos WK; Linn SC; Imholz ALT; Tjan-Heijnen VCG;
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29546343
[TBL] [Abstract][Full Text] [Related]
37. Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve.
Gleicher N; Weghofer A; Barad DH
Fertil Steril; 2010 Dec; 94(7):2824-7. PubMed ID: 20538269
[TBL] [Abstract][Full Text] [Related]
38. Ovarian cyst formation in patients using tamoxifen for breast cancer.
Metindir J; Aslan S; Bilir G
Jpn J Clin Oncol; 2005 Oct; 35(10):607-11. PubMed ID: 16254040
[TBL] [Abstract][Full Text] [Related]
39. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
40. Serum anti-müllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer. A follow-up study.
Al-Rawi SA; Saleh BO; Al-Naqqash MA
Saudi Med J; 2018 Jul; 39(7):733-735. PubMed ID: 29968900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
